Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Vac-Mn and Toripalimab in Metastatic Melanoma
NCT04072900Phase 1Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Apr 2020
- Primary completion
- Sep 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Neo-Vac-Mn in cutaneous melanoma (CM), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Number of participants experiencing adverse events at 252 days. Status: unknown.
02
Drugs
Neo-Vac-Mn
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04072900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072900.